An Analysis on Distribution and Inter-relationships of Biomarkers Under Rivaroxaban in Japanese Patients with Non-valvular Atrial Fibrillation (CVI ARO 1)
Year: March 15, 2018
Certara is the leading drug development consultancy with solutions spanning the discovery, preclinical and clinical stages of drug development.